Discordance Between Child‐Pugh and National Cancer Institute Classifications for Hepatic Dysfunction: Implications on Dosing Recommendations for Oncology Compounds

Guidance from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency recommends using Child‐Pugh classification for pharmacokinetic evaluation in noncancer subjects with hepatic impairment (HI). Therefore, dosing recommendations for oncology compounds for patients with HI are...

Descripción completa

Detalles Bibliográficos
Autores principales: Elmeliegy, Mohamed, Yang, Derek Z., Salama, Engie, Parivar, Kourosh, Wang, Diane D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754409/
https://www.ncbi.nlm.nih.gov/pubmed/32691438
http://dx.doi.org/10.1002/jcph.1702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754409/
https://www.ncbi.nlm.nih.gov/pubmed/32691438
http://dx.doi.org/10.1002/jcph.1702

Ejemplares similares